Beta-adrenergic blocking agents

Clinical Overview

Beta-adrenergic blocking agents—commonly known as beta-blockers—are a well-established class of medications widely used in cardiovascular, neurological, and endocrine disorders. These agents competitively inhibit beta-adrenergic receptors in the sympathetic nervous system, leading to reduced adrenergic stimulation of the heart, vasculature, kidneys, and other tissues. Depending on receptor selectivity, lipid solubility, and intrinsic sympathomimetic activity (ISA), beta-blockers are subclassified and selected for specific clinical indications.

---

1. Mechanism of Action

Beta-blockers inhibit the effects of catecholamines (epinephrine and norepinephrine) at beta-adrenergic receptors, thereby reducing:

• Heart rate (negative chronotropy)

• Contractility (negative inotropy)

• Conduction velocity (negative dromotropy)

• Renin secretion from juxtaglomerular cells (lowering blood pressure)

• Sympathetic tone in multiple organ systems

Receptor Subtypes:

• Beta-1 (β1): Predominantly in the heart and kidneys

• Beta-2 (β2): Found in lungs, vasculature, GI tract, liver, pancreas, uterus

• Beta-3 (β3): Involved in lipolysis and thermogenesis (limited clinical relevance)

---

2. Classification of Beta-Blockers

A. Based on Selectivity

Type	Description	Examples
Non-selective β-blockers	Block β1 and β2 receptors	Propranolol, Nadolol, Timolol
β1-selective (Cardioselective)	Preferentially block β1 receptors	Atenolol, Metoprolol, Bisoprolol, Esmolol
Non-selective with α1 blockade	Block β1, β2, and α1 receptors	Labetalol, Carvedilol

B. Based on Lipid Solubility (Affects CNS Penetration)

• High: Propranolol (CNS effects: depression, nightmares)

• Low: Atenolol, Nadolol (minimal CNS penetration)

C. Based on Intrinsic Sympathomimetic Activity (ISA)

• With ISA: Pindolol, Acebutolol – cause less bradycardia

• Without ISA: Most commonly used agents

D. Based on Duration of Action

• Short-acting: Esmolol (t½ ~9 min)

• Long-acting: Nadolol, Atenolol

---

3. Common Beta-Blocker Agents

Generic Name	Brand Name	Selectivity	Special Features
Propranolol	Inderal	Non-selective	High CNS penetration
Atenolol	Tenormin	β1-selective	Renal excretion, once daily
Metoprolol	Lopressor, Toprol XL	β1-selective	Available IV and oral; post-MI
Bisoprolol	Zebeta	β1-selective	Preferred in heart failure
Esmolol	Brevibloc	β1-selective	IV, ultra-short acting
Carvedilol	Coreg	β1, β2 + α1	Heart failure, antioxidant effect
Labetalol	Trandate	β1, β2 + α1	Hypertensive emergencies, pregnancy-safe
Nebivolol	Bystolic	β1-selective	NO-mediated vasodilation
Timolol	Timoptic	Non-selective	Ophthalmic use for glaucoma
Nadolol	Corgard	Non-selective	Long half-life (~20 hours)

4. Clinical Indications

A. Cardiovascular Conditions

• Hypertension (especially with co-morbid CAD)

• Ischemic heart disease (e.g., angina, post-MI)

• Congestive heart failure with reduced ejection fraction (HFrEF)

• Supraventricular arrhythmias (e.g., atrial fibrillation)

• Ventricular arrhythmias (adjunct)

• Hypertrophic obstructive cardiomyopathy (HOCM)

• Aortic dissection (β + α blocker preferred)

B. Neurological Indications

• Migraine prophylaxis (e.g., propranolol)

• Essential tremor

• Anxiety (performance-related) – propranolol

C. Ophthalmic Use

• Open-angle glaucoma (e.g., timolol drops)

D. Endocrine/Other Indications

• Thyrotoxicosis (symptom control)

• Pheochromocytoma (with α-blocker)

• Portal hypertension/variceal bleeding prophylaxis (propranolol, nadolol)

---

5. Pharmacokinetics

Agent	Half-Life	Lipid Solubility	Route
Atenolol	6–9 hours	Low	Oral
Metoprolol	3–7 hours (XL: 24 h)	Moderate	Oral, IV
Propranolol	3–6 hours	High	Oral, IV
Esmolol	~9 minutes	Low	IV only
Carvedilol	7–10 hours	Moderate	Oral
Nadolol	14–24 hours	Low	Oral

Metabolism: Hepatic (most), renal excretion (atenolol, nadolol)

---

6. Adverse Effects

Common:

• Bradycardia

• Fatigue, lethargy

• Dizziness, hypotension

• Cold extremities

• Exercise intolerance

CNS Effects (especially lipophilic agents):

• Depression

• Insomnia

• Nightmares

Respiratory:

• Bronchospasm (non-selective agents in asthmatics)

Metabolic:

• Mask hypoglycemia symptoms (tachycardia) in diabetics

• May alter lipid profiles: ↑ triglycerides, ↓ HDL (less so with newer agents)

Rebound Effects:

• Abrupt discontinuation may lead to angina, MI, or hypertensive crisis

---

7. Contraindications

• Severe bradycardia

• 2nd or 3rd-degree heart block (without pacemaker)

• Acute decompensated heart failure

• Cardiogenic shock

• Severe asthma or COPD (especially non-selective agents)

• Sick sinus syndrome

• Peripheral arterial disease with severe symptoms (relative)

---

8. Precautions

• Start low and titrate slowly, especially in heart failure

• Avoid abrupt withdrawal – taper over 1–2 weeks

• Monitor:

  • Heart rate (target >50–60 bpm)

  • Blood pressure

  • Blood glucose in diabetic patients

• Use β1-selective agents in asthma/COPD if beta-blocker needed

---

9. Drug Interactions

• Calcium channel blockers (verapamil, diltiazem): ↑ risk of bradycardia, AV block

• Insulin/sulfonylureas: May mask hypoglycemia

• Clonidine: Abrupt withdrawal with beta-blocker co-use → hypertensive crisis

• NSAIDs: May reduce antihypertensive efficacy

• Digoxin: Additive effect on AV nodal blockade

• CYP2D6 inhibitors (e.g., fluoxetine): Can increase levels of metoprolol

---

10. Special Considerations by Subtype

Subclass	Preferred Use Cases	Notes
β1-selective	Hypertension, CAD, HF, diabetics, asthma	Lower bronchospasm risk
Non-selective	Migraine, tremor, portal HTN, thyrotoxicosis	Avoid in asthma/COPD
β + α blockers	Heart failure, aortic dissection, HTN crisis	Carvedilol and labetalol used in emergencies
ISA-containing agents	Bradycardia-prone patients	Less reduction in HR and CO

11. Beta-Blockers in Heart Failure

Recommended (per ACC/AHA and ESC guidelines):

• Bisoprolol

• Carvedilol

• Metoprolol succinate (extended-release)

These agents improve:

• Left ventricular ejection fraction

• Hospitalization rates

• Mortality

---

12. Beta-Blocker Use in Pregnancy and Lactation

• Labetalol: First-line for gestational hypertension/preeclampsia

• Atenolol: Avoid in early pregnancy (risk of fetal growth restriction)

• Metoprolol: Considered relatively safe